Castle Creek gains US rights to vertigo treatment Arlevert

15 December 2016
castle-creek-pharmaceuticals-large

The USA's Castle Creek Pharmaceuticals has acquired the US rights to the vertigo drug Arlevert (cinnarizine, dimenhydrinate) from family-run German company Hennig Arzneimittel.

Financial terms of the deal were not disclosed.

"Our goal is to expedite the development of Arlevert in the USA by building on the European patient experience of more than 11 million prescribed doses and its track record of effectiveness"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical